Treatment with the experimental oral therapy GRI-0621 modulated immune cell activity in adults with idiopathic pulmonary fibrosis (IPF) in an early Phase 2a clinical trial, according to new data announced by its developer, Gri Bio. Data from the Phase 2a study (NCT06331624) broadly suggest that GRI-0621 is…